Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 8,400 shares, a growth of 29.2% from the February 13th total of 6,500 shares. Based on an average daily trading volume, of 8,800 shares, the short-interest ratio is currently 1.0 days. Currently, 0.7% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a research note on Thursday, December 5th.

Xenetic Biosciences Stock Up 3.2 %

Shares of NASDAQ XBIO opened at $3.50 on Monday. The business has a 50-day moving average price of $4.04 and a 200 day moving average price of $4.01. The stock has a market cap of $5.40 million, a PE ratio of -1.32 and a beta of 2.17. Xenetic Biosciences has a 52-week low of $2.78 and a 52-week high of $5.20.

Institutional Investors Weigh In On Xenetic Biosciences

A hedge fund recently raised its stake in Xenetic Biosciences stock. Renaissance Technologies LLC increased its holdings in shares of Xenetic Biosciences Inc (NASDAQ:XBIO) by 61.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,550 shares of the company’s stock after purchasing an additional 9,700 shares during the period. Renaissance Technologies LLC owned 1.66% of Xenetic Biosciences worth $102,000 as of its most recent SEC filing. Institutional investors and hedge funds own 15.12% of the company’s stock.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.